Connor, Clark & Lunn Investment Management (CC&L)’s Atossa Therapeutics ATOS Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,734	Closed	-$157K	–	1550
2025 Q4	$157K	Buy	17,734 +1,160	+7%	+$14.7K	﹤0.01%	1464
2025 Q3	$216K	Buy	16,574 +3,329	+25%	+$41.1K	﹤0.01%	1412
2025 Q2	$165K	Buy	13,245 +624	+5%	+$7.46K	﹤0.01%	1434
2025 Q1	$127K	Hold	12,621	–	–	﹤0.01%	1348
2024 Q4	$179K	Sell	12,621 -696	-5%	-$13.6K	﹤0.01%	1337
2024 Q3	$304K	Sell	13,317 -632	-5%	-$12.8K	﹤0.01%	1234
2024 Q2	$249K	Buy	13,949 +3,741	+37%	+$82.8K	﹤0.01%	1225
2024 Q1	$276K	Buy	10,208 +2,186	+27%	+$35.1K	﹤0.01%	1299
2023 Q4	$106K	Sell	8,022 -884	-10%	-$9.54K	﹤0.01%	1319
2023 Q3	$98.4K	Buy	+8,906	New	+$129K	﹤0.01%	1292
2023 Q1	–	Sell	-1,198	Closed	-$9.5K	–	1238
2022 Q4	$9.5K	Buy	+1,198	New	+$13.8K	﹤0.01%	1174

Other funds holding ATOS

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ATOS Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Atossa Therapeutics (ATOS) in Q1 2026, closing a stake of 17,734 shares — an estimated $157K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ATOS in Q4 2022 and held it in 11 quarters. The position peaked at $304K in Q3 2024. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Atossa Therapeutics position as of Q1 2026 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 17,734 Atossa Therapeutics shares in Q1 2026, an estimated $157K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Atossa Therapeutics in Q4 2022 and held it in 11 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Atossa Therapeutics position peaked at $304K in Q3 2024.
33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.